Left atrial appendage occlusion using the PLAATO system in high-risk patients with atrial fibrillation - Long-term follow-up

Postepy w Kardiologii Interwencyjnej

Volumn 5, Issue 2, 2009, Pages 51-57

  Kukuła, Krzysztof ^a   Kłopotowski, Mariusz ^a   Konka, Marek ^a   Witkowski, Adam ^a   Ruzyłło, Witold ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Atrial fibrillation; Left atrial appendage; PLAATO

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIVITAMIN K; ATENOLOL; BISOPROLOL; CARVEDILOL; CLOPIDOGREL; DIGOXIN; METOPROLOL; NITINOL; POLITEF; PROPAFENONE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; EUROPE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEART LEFT ATRIUM; HIGH RISK PATIENT; HUMAN; INTERVIEW; LOADING DRUG DOSE; MALE; PATHOLOGICAL ANATOMY; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PEROPERATIVE COMPLICATION; SCORING SYSTEM; SURGICAL EQUIPMENT; TELEPHONE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 68049089610     PISSN: 17349338     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001; 285: 2370-2375.
2. Crystal E, Connolly SJ. Role of oral anticoagulation in management of atrial fibrillation. Heart 2004; 90: 813-817.
3. Onalan O, Crystal E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. Stroke 2007; 38: 624-630.
4. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N.
5. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996; 61: 755-759.
6. Anderson DC, Kappelle LJ, Eliasziw M, et al. Occurrence of hemispheric and retinal ischemia in atrial fibrillation compared with carotid stenosis. Stroke 2002; 33: 1963-1967.
7. Harrison MJ, Marshall J. Atrial fibrillation. TIAs and completed strokes. Stroke 1984; 15: 441-442.
8. Lip GY, Boos CJ. Antithrombotic treatment in atrial fibrillation. Heart 2006; 92: 155-161.
9. Sherman DG, Kim SG, Boop BS, et al. National Heart, Lung, and Blood Institute AFFIRM Investigators. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med 2005; 165: 1185-1191.
10. Laupacis A, Boysen G, Connolly S, et al. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials. Arch Intern Med 1997; 157: 1237-1240.
11. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
12. Fang MC, Go AS, Chang Y, et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008; 51: 816-817.
13. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke. JAMA 2001; 285: 2864-2870.
14. Waldo AL, Becker RC, Tapson VF, et al. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005; 46: 1729-1736.
15. Hylek EM, D'Antonio J, Evans-Molina C, et al. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006; 37: 1075-1080.
16. Somerfield J, Barber PA, Anderson NE, et al. Not all patients with atrial fibrillation-associated ischemic stroke can be started on anticoagulant therapy. Stroke 2006; 37: 1217-1220.
17. Van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129: 1155-1166.
18. Kłopotowski M, Małek LA, Ruzyłło W. Direct factor Xa inhibitors in acute coronary syndromes. Post Kardiol Interw 2009; 1: 35-40.
19. Johnson WD, Ganjoo AK, Stone CD, et al. The left atrial appendage: our most lethal human attachment! Surgical implications. Eur J Cardiothorac Surg 2000; 17: 718-722.
20. Katz ES, Tsiamtsiouris T, Appelbaum RM, et al. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiographic study. J Am Coll Cardiol 2000; 36: 468-471.
21. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002; 105: 1887-1889.
22. Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multicenter feasibility trials. J Am Coll Cardiol 2005; 46: 9-14.
23. Bayard Y, Omran H, Kramer P, et al. Worldwide experience of percutaneous left atrial appendage transcatheter occlusion (PLAATO). J Neurol Sci 2005; 238: S70-S70.
24. Schmidt H, Hammerstingl C, von der Recke G, et al. Long-term follow-up in patients with percutaneous left atrial appendage transcatheter occlusion system (PLAATO): risk of thrombus formation and development of pulmonary venous obstruction after percutaneous left atrial appendage occlusion. J Am Coll Cardiol 2006; 47: 36A.
25. De Meester P, Thijs V, Van Deyk K, et al. Prevention of stroke by percutaneous left atrial appendage closure. Short term follow-up. Int J Cardiol 2008; article in press.
26. Hanna IR, Kolm P, Martin R, et al. Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): six-month echocardiographic follow-up. J Am Coll Cardiol 2004; 43: 1868-1872.
27. Healey JS, Crystal E, Lamy A, et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005; 150: 288-293.
28. Mobius-Winkler S, Schuler GC, Sick PB. Interventional treatments for stroke prevention in atrial fibrillation with emphasis upon the WATCHMAN device. Curr Opin Neurol 2008; 21: 64-69.
29. Bayard YL, Ostermayer SH, Sievert H. Alternatives to warfarin in atrial fibrillation: drugs and devices. Heart 2008; 94: 1113-1116.
30. Fountain RB, Holmes DR, Chandrasekaran K, et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J 2006; 151: 956-961.
31. http://www.theheart.org/article/951777.do, from i2 Summit of the American College of Cardiology 2009 Scientific Sessions
32. http://www.theheart.org/article/962955.do